Concepedia

Varun Garg

VG

Statistics

Publications

11

Citations

497

H-Index

11

Active since

1994

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Massachusetts General Hospital

Harvard University

Dana-Farber Cancer Institute

Varun Garg is an author at Vertex Pharmaceuticals (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

ORCID

Publications per year

1994–2021

11

Publications

11

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

Michael V. Seiden, Kenneth D. Swenerton, Ursula A. Matulonis et al. · Gynecologic Oncology · 2002 · 98 citations

, , +14

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.

Deborah Toppmeyer, Andrew D. Seidman, Michaël Pollak et al. · PubMed · 2002 · 84 citations

, , +16

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

David C. Dale, Frank Firkin, Audrey Anna Bolyard et al. · Blood · 2020 · 71 citations · Full text

, , +2

Bioavailability and reversible metabolism of prednisone and prednisolone in man

Varun Garg, William J. Jusko · Biopharmaceutics & Drug Disposition · 1994 · 64 citations

, , +11

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor

Varun Garg, Jinshan Shen, Chonghua Li et al. · Clinical and Translational Science · 2019 · 35 citations · Full text

, , +16

1–5 of 11